# Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Study · id `cardio:ct-nct02892149` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02892149](<https://clinicaltrials.gov/study/NCT02892149>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02892149

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3554 participants.

## Technical summary

Registry record NCT02892149. Randomized; no masking; primary purpose treatment. Start 2016-08 (actual); primary completion 2020-01-16 (actual). Results posted on 2022-06-28.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 3554 participants (enrolled count; ClinicalTrials.gov record NCT02892149, source copy `cardio:ctgov-nct02892149-2022-06-28`, retrieved 2026-10-26)
- Started: 2016-08 (actual) (ClinicalTrials.gov record NCT02892149, source copy `cardio:ctgov-nct02892149-2022-06-28`, retrieved 2026-10-26)
- Primary completion: 2020-01-16 (actual) (ClinicalTrials.gov record NCT02892149, source copy `cardio:ctgov-nct02892149-2022-06-28`, retrieved 2026-10-26)
- Completion: 2020-03-30 (actual) (ClinicalTrials.gov record NCT02892149, source copy `cardio:ctgov-nct02892149-2022-06-28`, retrieved 2026-10-26)
- Results first posted: 2022-06-28 (ClinicalTrials.gov record NCT02892149, source copy `cardio:ctgov-nct02892149-2022-06-28`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Brazil; Bulgaria; Canada; France; Germany; Israel; Italy; Mexico; Poland; Portugal; Russia; Serbia; South Korea; Ukraine; United Kingdom (ClinicalTrials.gov record NCT02892149, source copy `cardio:ctgov-nct02892149-2022-06-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02892149-2022-06-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
- Condition: Anemia
- Condition: Dialysis-Dependent Chronic Kidney Disease
- Intervention (Drug): Vadadustat
- Intervention (Drug): Darbepoetin alfa
- Lead sponsor: Akebia Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Akebia Therapeutics (`cardio:org-akebia-therapeutics`)

## Provenance

Content hash: 35d149ed3f9a413e0bb1e44b95cbc2d9ca28e6f05de91d9cd6c1a73c4941f599
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
